EP0816343A1 - Verfahren zur Herstellung chiraler, nicht racemischer (4-Aryl-2,5-dioxoimidazolidin-1-yl)-essigsäuren - Google Patents
Verfahren zur Herstellung chiraler, nicht racemischer (4-Aryl-2,5-dioxoimidazolidin-1-yl)-essigsäuren Download PDFInfo
- Publication number
- EP0816343A1 EP0816343A1 EP97109739A EP97109739A EP0816343A1 EP 0816343 A1 EP0816343 A1 EP 0816343A1 EP 97109739 A EP97109739 A EP 97109739A EP 97109739 A EP97109739 A EP 97109739A EP 0816343 A1 EP0816343 A1 EP 0816343A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- general formula
- racemic
- compound
- alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1(C(*)(C(N2*)=O)NC2=O)C=CC(*)=CC1 Chemical compound CC1(C(*)(C(N2*)=O)NC2=O)C=CC(*)=CC1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention relates to a process for the preparation of chiral, non-racemic compounds of the general formula I, represent the valuable intermediates for the production of active pharmaceutical ingredients, in which a salt is formed from the racemic compound of the general formula I and a chiral, non-racemic amino compound for the resolution of racemate. It further relates to compounds of general formula I and esters thereof.
- Enantiomerically pure hydantoin acetic acids which are suitable for the Manufacture of active ingredients with a uniform configuration at C-4 des Hydantoin rings are suitable, but according to PCT application PCT / EP96 / 01572 only available using complex processes in multi-step syntheses, for example by converting a carbonyl compound into a hydantoin in a Bucherer reaction is implemented, this is hydrolyzed to the amino acid, the amino acid esterified is carried out with the amino acid ester, a racemate splitting, which enantiomerically pure compound reacted with an isocyanatoacetic acid ester is and the product obtained finally under acidic conditions Hydantoinetic acid is cyclized.
- non-racemic Hydantoinetic acids of the general formula I in a simple manner and in high optical and chemical yields by resolution of racemates at the stage the easily accessible racemic compounds of the general formula I can be produced in the case of the racemic compound of the general formula I and a chiral, non-racemic amino compound, a salt is formed.
- the non-racemic hydantoin acetic acids of the general available thereby Formula I in which the C configuration at C-4 is uniform or predominantly the R configuration or the S configuration exists, can then be according to the information in the PCT application PCT / EP96 / 01572 produce the desired active ingredients.
- racemic resolution used racemic compounds of the general Formula I ie the enantiomeric mixtures
- racemic resolution used racemic compounds of the general Formula I can be according to or analogous to known methods, e.g. also according to the information in the PCT application PCT / EP94 / 03491.
- Alkyl radicals can be straight-chain or branched. This also applies if they are substituted. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, Isohexyl, n-heptyl. Preferred alkyl radicals are methyl, ethyl, n-propyl, isopropyl and tert-butyl, methyl and ethyl are particularly preferred.
- phenyl (C 1 -C 7 ) alkyl radicals the phenyl group can be located in any position in the alkyl group.
- phenyl (C 1 -C 7 ) alkyl radicals are benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl and 6-phenylhexyl.
- Preferred radicals are phenyl (C 1 -C 4 ) alkyl radicals, a particularly preferred radical is benzyl.
- cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cycloheptyl and cyclooctyl.
- Cycloalkyl radicals can also be one or more Alkyl radicals, especially methyl radicals, may be substituted.
- a preferred one Cycloalkyl is the cyclopropyl group.
- R 1 preferably represents chlorine, bromine, iodine, cyan or hydroxy, particularly preferably chlorine, bromine or cyan.
- R 2 preferably represents hydrogen, fluorine, (C 1 -C 4 ) -alkyl, in particular methyl or ethyl, phenyl- (C 1 -C 4 ) -alkyl, in particular benzyl, or (C 3 -C 7 ) -cycloalkyl, in particular cyclopropyl, particularly preferably for hydrogen, methyl or ethyl, very particularly preferably for methyl or ethyl, moreover preferably for methyl.
- R 1 simultaneously represents chlorine, bromine or cyano and R 2 represents methyl or ethyl.
- Preferred meanings of R 2 in the general formula II are hydrogen, (C 1 -C 4 ) -alkyl, in particular methyl and ethyl, phenyl- (C 1 -C 4 ) -alkyl, in particular benzyl, and (C 3 -C 7 ) -Cycloalkyl, especially cyclopropyl, particularly preferred meanings of R 2 in the general formula II are methyl and ethyl.
- the compounds of general formula II can under the known conditions of the Bucherer reaction (HT Bucherer, VA Lieb, J. Prakt. Chem. 141 (1934), 5-43) by reaction with potassium cyanide and ammonium carbonate in the racemic hydantoins of the general formula III, in which R 1 and R 2 are defined as indicated for the general formula II.
- the compounds of the general formula III can be used analogously to methods known from the literature (see, for example, Houben-Weyl, Methods of Organic Chemistry, Volume XI / 1, pp. 81ff, or M. Orena et al., J. Org. Chem.
- haloacetic acid esters of the general formula IV in which X is chlorine, bromine or iodine, in particular chlorine or bromine, and R 3 is , for example, (C 1 -C 6 ) -alkyl, in particular methyl, ethyl or tert-butyl, or benzyl, to N-1 the esters of the general formula V are alkylated in which R 1 and R 2 are as defined for the general formula III and R 3 is as defined for the general formula IV.
- a particularly preferred compound of the general formula IV is the chloroacetic acid methyl ester.
- catalytically active substances for example iodides such as potassium iodide or sodium iodide when using chloro- or bromoacetic acid esters
- iodides such as potassium iodide or sodium iodide when using chloro- or bromoacetic acid esters
- the esters of the general formula V can then be converted into the racemic hydantoin acetic acids of the general formula I by methods familiar to the person skilled in the art, for example using aqueous mineral acids such as hydrochloric acid or aqueous alkali metal hydroxide solutions such as sodium hydroxide solution.
- the conversion of the esters of the general formula V into the acids can be carried out directly after the alkylation without isolation of the ester, but the esters can also be isolated in between.
- a conversion of the substituent R 1 can also be carried out in the racemic compounds of the general formula I.
- compounds of general formula I, in which R 1 is halogen by an analog to known methods carried out halogen-cyano exchange, for example a bromo-cyano exchange, be converted into compounds of general formula I in which R 1 stands for cyan (N. Chatani and T. Hanafusa, J. Org. Chem. 51 (1986), 4714; JR Dalton and SL Regen, J. Org. Chem.
- R 1 can be converted directly or after conversion of the hydroxy group, for example into the methylsulfonyloxy group or the trifluoromethylsulfonyloxy group, by a cyan exchange into compounds in which R 1 is cyan (MRI Chambers and DA Widdowson, J. Chem. Soc. Perkin Trans I (1989), 1365; V. Percec et al., J. Org. Chem 60 (1995), 6895; and literature cited therein), and compounds in which R 1 represents hydrogen can be converted directly into compounds in which R 1 stands for cyan (G. Lohaus, Chem. Ber. 100 (19th 67), 2719). Such conversions can also be carried out in the non-racemic compounds of the general formula I.
- the salt formation to be carried out for the resolution of racemates from the racemic Compound of general formula I and chiral, non-racemic Amino compound is made by association according to the usual procedure of the two components in a solvent, diluent or dispersant.
- the subsequent actual racemate resolution, i.e. the separation or Enrichment or depletion of one of the two enantiomeric forms of Compound of the general formula I is then used using the different properties that the salt from the R form of the compound of general formula I and the chiral, non-racemic amino compound on the one hand and the salt from the S form of the compound of general formula I. and the chiral, non-racemic amino compound on the other hand.
- the two components can create the racemic compound of the general formula I are submitted and the amino compound are metered in or vice versa, and both components can be in the same time Reaction vessel are dosed.
- Amines which have no other functional groups besides amino groups Groups in the molecule, as well as amines, contain one or more contain further functional groups, e.g. Hydroxyl groups, ether groups, Carboxylic acid groups, carboxylate groups, ester groups or amide groups.
- the Amino compounds can be saturated or unsaturated and also aromatic Residues, especially unsubstituted or substituted phenyl, contain. she can contain primary, secondary and tertiary amino groups, and Amino groups can also be part of a ring system.
- Amines are preferred, Amino alcohols, amino acids and amino acid derivatives, particularly preferred Amino alcohols used.
- Suitable chiral amino compounds are (+) - phenylalanine, (-) - phenylalanine, (+) - ephedrine, (-) - ephedrine, (+) - norephedrine, (-) - norephedrine, (+) - phenylalaninol, (-) - phenylalaninol, (R) -phenylalanine methyl ester, (S) -phenylalanine methyl ester or (L) -N-methylglucosamine.
- solvent in which the racemic Compound of general formula I and the chiral, non-racemic Amino compound to form salt depends on the individual case, ie of the respective combination of amino compound and compound of general formula I and the properties of their salts and of the for the Racemate resolution proposed procedure.
- Suitable solvents are e.g. water and organic solvents such as alcohols e.g. Methanol, Ethanol, propanol and isopropanol, ether, e.g.
- tert-butyl methyl ether dioxane, Tetrahydrofuran and mono- and dimethyl ether of ethylene glycol and Diethylene glycol, ketones, e.g. Acetone and butanone, esters, e.g. Ethyl acetate and tert-butyl acetate, and hydrocarbons and halogenated hydrocarbons, e.g. B. Toluene and methylene chloride.
- Solvents are used, for example mixtures of water and Ethanol, from water and methanol, from isopropanol and tert-butyl methyl ether or from water and ethyl acetate, e.g. in the form of water saturated ethyl acetate. In many cases it is advisable to work in an aqueous organic solvent So in a mixture of water and one or more organic Solvents, or in water.
- racemic compound of general formula I and the chiral, not Racemic amino compounds can be combined to form salt in a molar ratio of 1: 1 be, but it can also be one of the two components in the deficit or in the Excess are used.
- 0.5 to 1 mol of amino compound are preferred to 1 mol of racemic compound of the general formula I used.
- up to 0.5 mol of auxiliary base per 1 mol are preferred racemic compound of general formula I used.
- Suitable as auxiliary bases e.g. Alkali hydroxides such as lithium, sodium or potassium hydroxide.
- Salt formation is generally carried out at temperatures from -15 ° C to 100 ° C, preferably 0 ° C to 80 ° C, carried out.
- a form for example, cannot distribute between two miscible liquid phases or an extraction.
- a certain enantiomer of the general formula I can be of advantage be to choose the conditions so that not the desired enantiomer as Salt with the chiral amino compound fails, but the undesirable, and that desired initially remains in the mother liquor.
- this contains Reaction mixture of salt formation, preferably 2.5 to 40 percent by weight, particularly preferably 10 to 30 percent by weight of racemic compound general formula I, based on the total weight of the reaction mixture.
- the temperature during the crystallization process is generally -15 ° C to 100 ° C, preferably 0 ° C to 80 ° C. It can change during crystallization e.g. can crystallize at a higher temperature be initiated and then the temperature lowered. In many cases it is favorable to set a temperature of -5 ° C to 30 ° C at the end.
- the salt or mother liquor that precipitates during the fractional crystallization contains one or the other enantiomeric form of the compound of the general Formula I often already in a high optical purity, for the synthesis of active ingredients is sufficient. If the enantiomer contained in the precipitated salt becomes higher If purity is desired, after isolating this salt e.g. by filtering or centrifuging a further enrichment e.g. by recrystallization be connected. This recrystallization, which is another fractional Crystallization represents, can be carried out one or more times until the im The desired optical purity is achieved in individual cases.
- solvents used in the recrystallization of the salts from the compounds of general formula I and the chiral, non-racemic amino compounds can be used, the above explanations regarding the solvents in salt formation apply corresponding.
- solvents in salt formation apply corresponding.
- water alcohols such as Methanol, ethanol or isopropanol, or mixtures thereof, e.g. Mixtures of Water and ethanol.
- the concentration of the salt used is preferably 2.5 to 40 percent by weight, particularly preferably 10 to 30 percent by weight, based on the total weight of the Recrystallization approach.
- the temperature during recrystallization is generally at -15 ° C to 100 ° C, preferably at 0 ° C to 80 ° C. In many cases it is favorable, in the end before isolating the precipitated crystals e.g. by Filter or centrifuge to set a temperature from -5 ° C to 30 ° C.
- the enantiomer which is in the form of its salt with the chiral Amino compound in the mother liquor after salt formation Crystallization is contained in a higher optical purity than that initially reached desired, e.g. some or all of the mother liquor be concentrated and the salt obtained according to the above statements be recrystallized.
- the release of the carboxylic acids of the general formula I is preferred Water or a mixture of water and an organic solvent, e.g. in a water-ethyl acetate mixture, carried out with aqueous mineral acid a pH of about 0 to 2 and the carboxylic acid by phase separation and / or extraction, e.g. with ethyl acetate, and then concentrating the organic phases and drying of the residue isolated. Analog, e.g. by acidification and extraction, for the described release from the isolated
- the carboxylic acids of the general formula I can also be obtained by salts, the salt formation in the mother liquor of a crystallized salt have remained. This applies to both carboxylic acids in the form of their salts with the chiral amino compounds remain in the mother liquor, as well as for salts with auxiliary bases added if necessary.
- non-racemic amino compound can be recovered. This can be done in such a way that the acidic solution with a strong base, e.g. an alkali hydroxide such as sodium hydroxide solution or potassium hydroxide solution, to a pH value of 11 or greater is set and then in the form of the free base Amino compound is isolated, e.g. by extracting from an aqueous solution or suspension with an organic solvent such as ethyl acetate, drying and concentrating the extracts.
- the recovered amino compound can before re-use in a racemate resolution e.g. by digesting with a solvent or by recrystallization.
- a preferred compound which is the subject of the present invention as such is the compound of the general formula Ia, in which R 1a is bromine and R 2a is methyl, in racemic form, ie the compound of the formula Ib in racemic form, which can be used as starting material in the process according to the invention described above.
- the products were identified by their 1 H NMR spectra and mass spectra.
- the enantiomeric excess (ee) of an acid of the general formula I on the (R) form or the (S) form in the products obtained was determined by high pressure liquid chromatography (HPLC) (column: S, S-Whelk-01 (250 mm x 4 mm) from E. Merck, Darmstadt; detector: UV 240/254 mm; eluent: n-hexane + ethanol + glacial acetic acid (90 + 10 + 1 volume parts); flow: 1 ml / min; temperature: 40 ° C).
- the salts obtained in the examples were examined directly by HPLC.
- the absolute configuration of the compounds of the general formula I was determined via the independent preparation of the non-racemic compounds from the corresponding optically pure amino acids known from the literature (cf. PCT application PCT / EP96 / 01572).
- the aqueous phase is three times extracted with 40 ml of ethyl acetate each.
- the combined organic phases are washed three times with 25 ml of saturated sodium chloride solution.
- the Sodium chloride solutions are discarded.
- the organic phase is mixed with 100 ml dilute sodium hydroxide solution and the mixture over a Seitz filter layer filtered.
- the organic phase is separated and discarded, the alkaline aqueous Phase is adjusted to a pH of 1 to 1.5 with concentrated hydrochloric acid acidified.
- the initially oily product crystallizes after a short time.
- the mixture is stirred at 10 ° C for 1 h, the product is filtered off, washed neutral with water and dries. Yield: 7.5 g (72%) of the racemic title compound.
- Example 18 The product obtained according to Example 18 is made twice from boiling isopropanol recrystallized, initially slowly with stirring to 20 to 25 ° C. Allow to cool and then leave to stand at 5 ° C overnight. The unusual product is filtered off and dried. Yield: 8.4 g of the title salt with 99.5% ee (S) acid (HPLC).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Ausbeute: 4.4 g des (R)-Phenylalaninol-Salzes der Titelsäure.
[α]20 D = +18° (c = 1; 2.15 N ethanolische Chlorwasserstofflösung).
[α]20 D = -18° (c=1; Methanol)
[α]20 D = +56° (c = 1; 29.2 %ige ethanolische Chlorwasserstofflösung).
[α]20 D = +25.5° (c = 1.2; 1 N wäßrige Chlorwasserstofflösung)
Ausbeute: 10.8g des Titelsalzes mit 94.4% ee der (R)-Säure (HPLC). Schmp. 199 bis 201 °C.
Ausbeute: 8.8 g des Titelsalzes mit ≤ 1 % ee der Säure (HPLC).
Claims (14)
- Verfahren zur Herstellung chiraler, nicht racemischer Verbindungen der allgemeinen Formel I, in derR1 für Wasserstoff, Fluor, Chlor, Brom, Iod, Cyan, Nitro oder Hydroxy steht undR2 für Wasserstoff, Fluor, (C1-C7)-Alkyl, Phenyl-(C1-C7)-alkyl oder (C3-C8)-Cycloalkyl steht, dadurch gekennzeichnet, daß eine Racematspaltung mit der racemischen Verbindung der allgemeinen Formel I durchgeführt wird, bei der aus der racemischen Verbindung der allgemeinen Formel I und einer chiralen, nicht racemischen Aminoverbindung ein Salz gebildet wird.
- Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß R1 für Chlor, Brom, Iod, Cyan oder Hydroxy steht.
- Verfahren gemäß Anspruch 1 und/oder 2, dadurch gekennzeichnet, daß R2 für Wasserstoff, Fluor, (C1-C4)-Alkyl, Benzyl oder (C3-C7)-Cycloalkyl, bevorzugt für Wasserstoff, Methyl oder Ethyl, steht.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß zur Herstellung der in die Racematspaltung eingesetzten racemischen Verbindungen der allgemeinen Formel I eine Carbonylverbindung der allgemeinen Formel II, in derR1 für Wasserstoff, Fluor, Chlor, Brom, Iod, Cyan, Nitro oder Hydroxy steht undR2 für Wasserstoff, (C1-C7)-Alkyl, Phenyl-(C1-C7)-alkyl oder (C3-C8)-Cycloalkyl steht,
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß als chirale, nicht racemische Aminoverbindungen Amine, Aminoalkohole, Aminosäuren oder Aminosäurederivate, bevorzugt Aminoalkohole, eingesetzt werden.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß bei der Salzbildung eine nicht chirale Hilfsbase zugesetzt wird.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 6, dadurch gekennzeichnet, daß die Bildung des Salzes aus der Verbindung der allgemeinen Formel I und der chiralen, nicht racemischen Aminoverbindung in Wasser, wäßrig-organischen Lösungsmitteln oder Alkoholen durchgeführt wird, wobei als Alkohole Methanol, Ethanol und Isopropanol bevorzugt sind.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß ein aus der Verbindung der allgemeinen Formel I und der chiralen, nicht racemischen Aminoverbindung gebildetes Salz fraktionierend kristallisiert wird und nach Isolierung gewünschtenfalls anschließend umkristallisiert wird.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 8, dadurch gekennzeichnet, daß aus einem Salz aus der Verbindung der allgemeinen Formel I und der chiralen, nicht racemischen Aminoverbindung durch Behandlung mit einer Mineralsäure die freie Carbonsäure der allgemeinen Formel I freigesetzt wird.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 9, dadurch gekennzeichnet, daß (S)-(4-(4-Cyanphenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)essigsäure hergestellt wird.
- Verbindungen der allgemeinen Formel Ia, in derR1a für Fluor, Chlor, Brom oder Hydroxy steht undR2a für (C1-C4)-Alkyl oder Benzyl steht,
- Verbindung der allgemeinen Formel Ia gemäß Anspruch 11, in der R1a für Brom und R2a für Methyl steht, in racemischer Form.
- Verbindungen der allgemeinen Formel Va gemäß Anspruch 13, in der R1a für Brom, R2a für Methyl und R3a für (C1-C4)-Alkyl steht, in racemischer Form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19624604 | 1996-06-20 | ||
DE19624604A DE19624604A1 (de) | 1996-06-20 | 1996-06-20 | Verfahren zur Herstellung chiraler, nicht racemischer (4-Aryl-2,5-dioxoimidazolidin-1-yl)essigsäuren |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0816343A1 true EP0816343A1 (de) | 1998-01-07 |
EP0816343B1 EP0816343B1 (de) | 2005-12-14 |
Family
ID=7797472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97109739A Expired - Lifetime EP0816343B1 (de) | 1996-06-20 | 1997-06-16 | Verfahren zur Herstellung chiraler, nicht racemischer (4-Aryl-2,5-dioxoimidazolidin-1-yl)-essigsäuren |
Country Status (11)
Country | Link |
---|---|
US (1) | US6018053A (de) |
EP (1) | EP0816343B1 (de) |
JP (1) | JP4199318B2 (de) |
KR (1) | KR980002030A (de) |
AT (1) | ATE312824T1 (de) |
AU (1) | AU724816B2 (de) |
CA (1) | CA2208129C (de) |
DE (2) | DE19624604A1 (de) |
DK (1) | DK0816343T3 (de) |
ES (1) | ES2253761T3 (de) |
HU (1) | HUP9701071A3 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050203156A1 (en) * | 2004-03-12 | 2005-09-15 | Wyeth | Hydantoins having RNase modulatory activity |
JPWO2015029447A1 (ja) * | 2013-08-30 | 2017-03-02 | 興和株式会社 | 光学活性カルビノール化合物の製造方法 |
JPWO2015037243A1 (ja) * | 2013-09-12 | 2017-03-02 | 興和株式会社 | 光学活性ヒダントイン化合物の製造方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0132854A2 (de) * | 1983-07-27 | 1985-02-13 | Nobel Chemicals AB | Verfahren zur optischen Trennung der (+/-)2-(6'-Methoxy-2'-naphthyl)propionsäuren |
EP0182279A1 (de) * | 1984-11-22 | 1986-05-28 | ALFA WASSERMANN S.p.A. | Verfahren zur optischen Auftrennung racemischer Gemische von alpha-Naphthylpropionsäuren |
EP0468592A2 (de) * | 1990-07-27 | 1992-01-29 | Westspur Investments Limited | Verfahren zur Herstellung von S(+)-6-Methoxy-alpha-methyl-2-naphthalin-Essigsäure |
EP0529835A2 (de) * | 1991-08-23 | 1993-03-03 | NAGASE & COMPANY, LTD. | Optische Spaltung von (+/-)-2-(4-Isobutylphenyl)propionsäure |
WO1995014008A1 (de) * | 1993-11-15 | 1995-05-26 | Hoechst Aktiengesellschaft | Substituierte 5-ring-heterocyclen, ihre herstellung und ihre verwendung |
WO1996033976A1 (de) * | 1995-04-28 | 1996-10-31 | Hoechst Aktiengesellschaft | Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2829157A (en) * | 1953-03-10 | 1958-04-01 | Leonard L Mckinney | Novel hydantoic acids and their alkyl esters |
US3939175A (en) * | 1973-05-07 | 1976-02-17 | Ciba-Geigy Corporation | Hydroxyphenylated hydantoins |
US5411981A (en) * | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
AT398199B (de) * | 1992-11-27 | 1994-10-25 | Chemie Linz Gmbh | Verfahren zur herstellung von arylhydantoinen |
-
1996
- 1996-06-20 DE DE19624604A patent/DE19624604A1/de not_active Withdrawn
-
1997
- 1997-06-16 ES ES97109739T patent/ES2253761T3/es not_active Expired - Lifetime
- 1997-06-16 AT AT97109739T patent/ATE312824T1/de active
- 1997-06-16 DE DE59712519T patent/DE59712519D1/de not_active Expired - Lifetime
- 1997-06-16 DK DK97109739T patent/DK0816343T3/da active
- 1997-06-16 EP EP97109739A patent/EP0816343B1/de not_active Expired - Lifetime
- 1997-06-19 US US08/879,289 patent/US6018053A/en not_active Expired - Lifetime
- 1997-06-19 CA CA002208129A patent/CA2208129C/en not_active Expired - Fee Related
- 1997-06-19 AU AU26135/97A patent/AU724816B2/en not_active Ceased
- 1997-06-19 HU HU9701071A patent/HUP9701071A3/hu unknown
- 1997-06-19 KR KR1019970025616A patent/KR980002030A/ko active IP Right Grant
- 1997-06-19 JP JP16173897A patent/JP4199318B2/ja not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0132854A2 (de) * | 1983-07-27 | 1985-02-13 | Nobel Chemicals AB | Verfahren zur optischen Trennung der (+/-)2-(6'-Methoxy-2'-naphthyl)propionsäuren |
EP0182279A1 (de) * | 1984-11-22 | 1986-05-28 | ALFA WASSERMANN S.p.A. | Verfahren zur optischen Auftrennung racemischer Gemische von alpha-Naphthylpropionsäuren |
EP0468592A2 (de) * | 1990-07-27 | 1992-01-29 | Westspur Investments Limited | Verfahren zur Herstellung von S(+)-6-Methoxy-alpha-methyl-2-naphthalin-Essigsäure |
EP0529835A2 (de) * | 1991-08-23 | 1993-03-03 | NAGASE & COMPANY, LTD. | Optische Spaltung von (+/-)-2-(4-Isobutylphenyl)propionsäure |
WO1995014008A1 (de) * | 1993-11-15 | 1995-05-26 | Hoechst Aktiengesellschaft | Substituierte 5-ring-heterocyclen, ihre herstellung und ihre verwendung |
WO1996033976A1 (de) * | 1995-04-28 | 1996-10-31 | Hoechst Aktiengesellschaft | Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, vol. 62, no. 5, 1 March 1965, Columbus, Ohio, US; abstract no. 5268bcd, column 5268; XP002042157 * |
H. U. STILZ ET AL.: "From peptides to heterocyclic peptide mimetics - design and synthesis of an orally active fibrinogen receptor antagonist for the prevention of thrombosis", BULLETIN DES SOCIETES CHIMIQUES BELGES, vol. 105, no. 10-11, October 1996 (1996-10-01), pages 711 - 9, XP002042155 * |
J. FALBE ET AL. (HRSG.): "Römpp Chemie Lexikon, 9. Auflage, Bd. 5, Pl-S", 1992, G. THIEME VERLAG, STUTTGART, DE, XP002042156 * |
J. Med. Chem., 1965, 8 (1), 117-120 und 120-122 * |
N. BUCKLEY ET AL.: "A reinvestigation of the alkylation of 5-(p-hydroxyphenyl)-5-phenylhydantoin", CLINICA CHIMICA ACTA, vol. 62, 1975, pages 73 - 8, XP002042308 * |
Also Published As
Publication number | Publication date |
---|---|
HU9701071D0 (en) | 1997-08-28 |
KR980002030A (ko) | 1998-03-30 |
CA2208129A1 (en) | 1997-12-20 |
HUP9701071A2 (hu) | 1998-04-28 |
JPH1059947A (ja) | 1998-03-03 |
DE59712519D1 (de) | 2006-01-19 |
HUP9701071A3 (en) | 1999-08-30 |
DE19624604A1 (de) | 1998-01-02 |
ES2253761T3 (es) | 2006-06-01 |
AU724816B2 (en) | 2000-09-28 |
DK0816343T3 (da) | 2006-04-10 |
EP0816343B1 (de) | 2005-12-14 |
ATE312824T1 (de) | 2005-12-15 |
CA2208129C (en) | 2007-01-02 |
JP4199318B2 (ja) | 2008-12-17 |
AU2613597A (en) | 1998-01-08 |
US6018053A (en) | 2000-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0414275A2 (de) | Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte | |
EP0146080B1 (de) | Verfahren zur Racematspaltung bicyclischer Imino-alpha-carbonsäureester | |
EP3271337B1 (de) | Verfahren zur herstellung von (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitril | |
EP0312726A1 (de) | Optisch aktive Salze aus einem substituierten Thiazolidin-4-carboxylat und 3-Chlor-2-hydroxypropyltrimethylammonium, deren Herstellung und Verwendung | |
DE2449492A1 (de) | Verfahren zur herstellung von optisch aktivem p-hydroxyphenylglycin | |
DE60004126T2 (de) | Verfahren zur Herstellung von (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptan und ihre pharmazeutisch akzeptierbaren Säure-Additions-Salze | |
CH639639A5 (en) | Alpha-fluoromethyl-alpha-amino-alkanoic acids and their esters | |
DE112020001032T5 (de) | Verfahren zur Herstellung von Levoamphetamin | |
EP0816343B1 (de) | Verfahren zur Herstellung chiraler, nicht racemischer (4-Aryl-2,5-dioxoimidazolidin-1-yl)-essigsäuren | |
CH653996A5 (de) | Tryptaminderivate und verfahren zu deren herstellung. | |
DE3590085C2 (de) | ||
AT392068B (de) | Optisch aktive oxo-isoindolinylderivate | |
DE69804853T2 (de) | Verfahren zur herstellung von mequitazin und zwischenprodukt der synthese | |
EP0237630B1 (de) | Verfahren zur Herstellung chiraler Glycinderivate | |
DE69916269T2 (de) | Neues verfahren | |
DE69205685T2 (de) | 2-aminonaphthyridin-derivat, seine herstellung und verwendung. | |
DE2708143C3 (de) | 3-Carboxyphenylessigsäurederivate und Verfahren zu ihrer Herstellung | |
DE3931134C2 (de) | Verfahren zur Epimerisierung einer formalen Hydroxygruppe in einem Ester | |
DE3621835A1 (de) | Verfahren zur racemisierung optisch aktiver (alpha)-phenoxypropionsaeure und deren derivate | |
DE3342524C2 (de) | ||
DE3906460C1 (de) | ||
EP0027956A1 (de) | Verfahren zur Herstellung von (1-(4-Chlorbenzoyl)-5-methoxy-2-methyl-3-indol)acetoxyessigsäure | |
DE19947953A1 (de) | Verfahren zur selektiven Spaltung cyclischer Carbonsäureanhydride | |
DE4023773A1 (de) | Verfahren zur optischen auftrennung von zur herstellung von diltiazem geeigneten zwischenprodukten | |
EP0799824A1 (de) | Verfahren zur Herstellung von Carbonsäuresuccinimidylestern |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17P | Request for examination filed |
Effective date: 19980707 |
|
AKX | Designation fees paid |
Free format text: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030220 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH |
|
RTI1 | Title (correction) |
Free format text: PROCESS FOR THE PREPARATION OF CHIRAL, NON-RACEMIC (4-ARYL-2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACIDS |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REF | Corresponds to: |
Ref document number: 59712519 Country of ref document: DE Date of ref document: 20060119 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20060315 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20060400556 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2253761 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20060915 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20110621 Year of fee payment: 15 Ref country code: CH Payment date: 20110614 Year of fee payment: 15 Ref country code: PT Payment date: 20110615 Year of fee payment: 15 Ref country code: LU Payment date: 20110621 Year of fee payment: 15 Ref country code: SE Payment date: 20110613 Year of fee payment: 15 Ref country code: IE Payment date: 20110610 Year of fee payment: 15 Ref country code: GR Payment date: 20110511 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20110621 Year of fee payment: 15 Ref country code: GB Payment date: 20110615 Year of fee payment: 15 Ref country code: FI Payment date: 20110610 Year of fee payment: 15 Ref country code: DK Payment date: 20110610 Year of fee payment: 15 Ref country code: AT Payment date: 20110526 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20110614 Year of fee payment: 15 Ref country code: DE Payment date: 20110608 Year of fee payment: 15 Ref country code: IT Payment date: 20110617 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20110715 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20121217 |
|
BERE | Be: lapsed |
Owner name: *SANOFI-AVENTIS DEUTSCHLAND G.M.B.H. Effective date: 20120630 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20130101 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL Ref country code: AT Ref legal event code: MM01 Ref document number: 312824 Country of ref document: AT Kind code of ref document: T Effective date: 20120616 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121217 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120617 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20060400556 Country of ref document: GR Effective date: 20130104 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130101 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120702 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120630 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120630 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130101 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120630 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 59712519 Country of ref document: DE Effective date: 20130101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120702 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20131018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120617 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 |